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CCAAT enhancer binding protein  (C/EBP) plays an essential role
in the cascade that triggers adipocyte differentiation. C/EBP
activates transcription of C/EBP and peroxisome proliferator-
activated receptor-, transcriptional activators of genes that give
rise to the adipocyte phenotype. Sequential phosphorylation of
C/EBP/liver activating protein (LAP) on Thr188 by MAPK and on
Ser184 or Thr179 by glycogen synthase kinase  (GSK3) is required
for acquisition of DNA binding activity and transcriptional activa-
tion. To investigate how phosphorylation and dimerization of
C/EBP/LAP alter these activities, wild-type (Wt) and mutant
rC/EBPs were prepared and purified to assess DNA binding and
transcription in cell-free systems. rC/EBP/LAP, phosphorylated by
MAPK and GSK3 in vitro, produced a >100-fold increase in DNA
binding activity. Mutation of the phosphorylation to Glu increased
DNA binding activity. Using a cell-free transcription system with
nuclear extract from 3T3-L1 preadipocytes and rC/EBP/LAP, only
doubly phosphorylated rC/EBP/LAP (by MAPK and GSK3) acti-
vated transcription driven by Wt C/EBP, 422/aP2, and SCD1
promoters. Oxidation-induced dimerization of doubly phosphory-
lated Wt rC/EBP/LAP increased DNA binding, whereas unphos-
phorylated Wt rC/EBP/LAP lacked DNA binding activity. Mutation
of the C-terminal Cys296 adjacent to the leucine zipper and Cys143
just upstream of the DNA binding domain eliminated phosphory-
lation-, oxidation-, and dimerization-dependent DNA binding ac-
tivity, whereas mutation of Cys201 within the basic DNA binding
domain had little effect on DNA binding. These findings indicate
that dual phosphorylation of C/EBP/LAP caused a conformational
change that facilitates S–S bond formation and dimerization,
rendering the basic region accessible to the C/EBP regulatory
element.
adipocyte differentiation  disulfide bond  transactivation
D ifferentiation of growth-arrested 3T3-L1 preadipocytes intoadipocytes is induced by hormonal stimuli that trigger
expression of CCAAT enhancer binding protein  (C/EBP)
(1–3) and, thereby, a transcriptional cascade that gives rise to the
adipocyte phenotype. C/EBP activates the expression of the
genes for two pleiotropic transcription factors, C/EBP and
PPAR (4, 5), which in turn activate the expression of numerous
adipogenic genes. Although maximal expression of C/EBP
occurs rapidly (within 2–4 h) on induction of differentiation and
remains at this level over the next 48 h, the acquisition of DNA
binding activity by C/EBP required for the expression of
C/EBP and PPAR only occurs after a long lag period of
12–14 h (1, 2, 6). At the end of the lag period, growth-arrested
preadipocytes synchronously enter the cell cycle and undergo
several rounds of mitotic clonal expansion (2, 3), a process
required for subsequent differentiation. It is believed that chro-
matin remodeling occurs during mitotic clonal expansion and is
a prerequisite of terminal differentiation. Presumably, this delay
prevents the premature expression of C/EBP, which is anti-
mitotic, and allows mitotic clonal expansion and chromatin
remodeling to occur before its expression (5, 7).
We recently showed that C/EBP must undergo sequential
phosphorylation to acquire DNA binding ability (6). Immedi-
ately after the expression of C/EBP, a ‘‘priming’’ phosphory-
lation occurs on Thr188 catalyzed by MAP kinase, which is
required but is insufficient for acquisition of DNA binding
activity. After the lag period (at the G13 S phase checkpoint),
glycogen synthase kinase  (GSK3) translocates from the
cytoplasm into the nucleus and phosphorylates C/EBP on
Ser184 or Thr179, giving rise to DNA binding activity (6). These
and other findings suggest that dual phosphorylation of C/EBP
induces a conformational change that leads to acquisition of
DNA binding activity possibly by exposing the DNA binding
domain.
An impediment to investigating the mechanism by which phos-
phorylation alters the DNA binding activity of C/EBP is the
complexity of the mixture of leucine zipper proteins in nuclear
extracts of 3T3-L1 cells. This mixture includes several C/EBP family
members that are capable of forming homo- and heterodimers,
including three C/EBP isoforms [i.e., flC/EBP (39 kDa),
C/EBP/liver activating protein (LAP) (38 kDa), and dominant-
negative C/EBP/liver inhibiting protein (LIP) (18 kDa)] (8);
C/EBP (9, 10); and dominant-negative CHOP-10 (11). All of these
factors are found in nuclear extract of 3T3-L1 cells after the
induction of differentiation. Because these leucine zipper transcrip-
tion factors can homo- and heterodimerize (12), interpretation of
binding data with nuclear extracts becomes difficult. To circumvent
these difficulties, the present investigation used purified rC/EBP/
LAP to evaluate the effects of phosphorylation and -SS-bond-
induced dimerization on the DNA binding activity and transacti-
vation capacity. Our findings indicate that the dual phosphorylation
of C/EBP/LAP leads to a conformational change that facilitates
dimerization, rendering the DNA binding domain accessible to the
C/EBP regulatory element in DNA.
Results and Discussion
Recombinant C/EBP/LAP Is Phosphorylated by MAPK and GSK3.
GST-rC/EBP/LAP was prepared by using an expression system
that produced a substantial quantity of the protein in the native
state. The protein was partially purified by GSH-agarose chro-
matography, followed by cleavage with PreScission protease and
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final purification to homogeneity by CM-Sepharose ion ex-
change chromatography (Fig. 1A). The apparent molecular mass
of rC/EBP/LAP was 34 kDa (or 35 kDa when phosphorylated
by MAPK). Recombinant C/EBP/LAP is phosphorylated by
MAPK alone and is further phosphorylated by GSK3, but only
after a ‘‘priming’’ phosphorylation by MAPK (Fig. 1B).
In experiments designed to fragment rC/EBP/LAP, we de-
termined that cleavage by thrombin occurs at two sites, giving
rise to 3-, 14-, and 17-kDa fragments. As illustrated in Fig. 1C,
three protein species of 34-, 31-, and 17-kDa molecular mass
were evident by protein staining of SDS/PAGE gels during the
course of proteolysis (Fig. 1C). The 31- and 14-kDa fragments
were identified on SDS/PAGE gels with anti-C/EBP/LAP
N-terminal antibody, whereas the 31- and 17-kDa fragments
formed during proteolysis were identified with anti-C/EBP/
LAP C-terminal antibody. The N- and C-terminal epitopes of
the antibodies are shown at the bottom of Fig. 1C. The phos-
phorylation sites (Ser184, Thr179, and Thr188) are located in the
C-terminal 17-kDa fragment.
DNA Binding Activity Is Increased by Dual Phosphorylation by MAPK
and GSK3. Recombinant C/EBP/LAP was phosphorylated by
MAPK and/or GSK3 as described in Fig. 1B and then subjected
to electrophoretic mobility shift assay (EMSA) with a labeled
oligonucleotide corresponding to the C/EBP regulatory element
in the C/EBP gene promoter. Substantial DNA binding was
detected with only 1 ng¶ of rC/EBP/LAP after dual phosphor-
ylation by MAPK and GSK3, with virtually no binding occur-
ring in the absence of either (Fig. 2A). Although increasing the
level of rC/EBP/LAP by 10-fold led to detectable DNAbinding,
even with either MAPK or GSK3 alone, dual phosphorylation
of rC/EBP/LAP by both kinases led to a 100-fold in DNA
binding than by either kinase alone. It should be noted that
previous mass spectrometric analysis showed conclusively that
dual phosphorylation by MAPK and GSK3 occurs at Thr188
and either Ser184 or Thr179 (6).
These findings were verified with the C/EBP regulatory ele-
ments of several other promoters of genes that are transactivated
by members of the C/EBP family of transcription factors. DNA
binding activities were measured with nuclear extract from
3T3-L1 cells obtained at 4 h (before acquisition of DNA binding
activity) or 24 h (after acquisition of DNA binding activity) (1,
6) after the induction of differentiation (Fig. 2B). The C/EBP
regulatory elements of the C/EBP, aP2/422, SCD1, PPAR,
and GLUT4 gene promoters exhibited patterns similar to that of
the C/EBP promoter element (i.e., stronger binding activity by
24- than by 4-h nuclear extracts). Further, as shown in Fig. 2B,
rC/EBP/LAP exhibits DNA binding to this group of promoter
elements only after dual phosphorylation by MAPK and
GSK3.
We also determined the effect of mutating the phosphorylation
site Thr and Ser residues to Glu in an attempt to constitutively
mimic the effect of phosphorylation. The three phosphorylation
sites, Thr179, Ser184, and Thr188, were mutated to Ala or Glu. In a
previous report we showed thatmutation of Thr188 toAla abolished
the DNA binding response to dual phosphorylation by MAPK and
GSK3 (6). Doubly mutated Thr179/Thr188 to Glu179/Glu188 (ESE
mutant) provoked increased DNA binding relative to the AAA or
TSA mutations, albeit less than that of the dually phosphorylated
wild-type (Wt) construct (Fig. 2C). ESE mutant exhibited higher
DNA binding activity than TEE mutant. As previously shown by
LC-MS/MS analysis, C/EBP/LAP is dually phosphorylated on
either Thr179/Thr188 or Ser184/Thr188. However, the triply phosphor-
ylated form has never been detected (6). Therefore, of the two
possible combinations of dual phosphorylation, Thr179/Thr188 ap-
pears to be more effective than Thr184/Thr188 in activating DNA
binding. Although dual-Glu substitutions increase DNA binding,
they do not achieve the activity of the dually phosphorylated form
presumably because Glu mutants do not produce the optimal
conformation required for maximal DNA binding activity. Taken
together, however, these results show that dual phosphorylation of
¶As quantified by comparative EMSA experiments, 1 ng of pure rC/EBP/LAP is equivalent
to the amount of C/EBP/LAP present in 5 g of nuclear extract protein from 3T3-L1 cells
24 h after the induction of differentiation.
Fig. 1. Purification and in vitro phosphorylation of rC/EBP/LAP. (A) After
digestion of GST-rC/EBP/LAP with PreScission Protease, the rC/EBP/LAP was
subjected to CM-Sepharose ion-exchange column chromatography and
eluted by increasing [NaCl]. An aliquot (5l) of each fraction was subjected to
SDS/12% PAGE, and the gel was stained with Coomassie Brilliant Blue G-250.
(B) Purified rC/EBP/LAP was phosphorylated with [-32P]ATP, MAPK, and/or
GSK3 and subjected to SDS/PAGE. (C) (Upper) rC/EBP/LAP was incubated
with thrombin (1 unit) for the indicated time, subjected to SDS/12% PAGE, and
stained or immunoblotted with anti-C/EBP/LAP N- or C-terminal antibody.
(Lower) Schematic representation of the location of thrombin cleavage and
phosphorylation sites.
Fig. 2. DNA binding activity is increased by dual phosphorylation.
(A) rC/EBP/LAP was phosphorylated by MAPK and/or GSK3 and analyzed by
EMSA by using a nucleotide corresponding to the C/EBP regulatory element in
C/EBP promoter as a probe. (B) EMSA with the C/EBP binding-site probes
present in various adipocyte-specific promoters. Nuclear extract (NE) from
3T3-L1 cells (4 or 24 h after induction of differentiation) or rC/EBP/LAP was
incubated with MAPK (M) and/or GSK3 (G) and different C/EBP-site probes
and then subjected to EMSA. (C) Wt or phosphorylation-site mutants of
rC/EBP/LAPs [Thr179, Ser184, or Thr188 mutated to Ala (A) or Glu (E)] were
phosphorylated with MAPK and/or GSK3 as in A and B and subjected to
EMSA.
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C/EBP/LAP is required for increased binding to adipocyte gene-
specific promoters.
Cell-Free Transcription of Adipocyte-Specific Promoters Is Activated
by Dual Phosphorylation. Although exposure of 3T3-L1 preadipo-
cytes to inhibitors of MAPK or GSK3 prevents C/EBP/LAP-
dependent processes (i.e., mitotic clonal expansion and terminal
differentiation) (6), questions remain as to whether these effects
are due solely to a blockade of C/EBP phosphorylation. To
directly assess the effect of phosphorylation of C/EBP/LAP on
transcriptional activation, we used the cell-free transcription
system used previously in our laboratory (13). Nuclear extracts
from 3T3-L1 preadipocytes or adipocytes provided the basal
transcriptional machinery along with rC/EBP/LAP that had (or
had not) been phosphorylated by MAPK and/or GSK3. The
promoters of several adipocyte-specific genes [i.e., the C/EBP
(4), aP2/422 (13), and SCD1 (14) genes] were fused to a
luciferase reporter and served as DNA templates. The resulting
RNA transcripts were analyzed by PCR. In the absence of
nuclear extract or rC/EBP/LAP, no PCR product was detected
(Fig. 3A), indicating the effectiveness of removal of the luciferase
template with DNase1. In the presence of nuclear extract from
day-2 3T3-L1 cells, transcription driven by the aP2/422 promoter
was increased compared with that from day-0 cells, consistent
with the fact that aP2/422 is expressed by 3T3-L1 preadipocytes
2 days after the induction of differentiation (5). To determine
the effect of dual phosphorylation, rC/EBP/LAP was first
incubated with and/or withoutMAPK andGSK3 and then with
day-0 preadipocyte nuclear extract and the other components of
the cell-free transcription system. As shown in Fig. 3A, tran-
scription was activated by 10-fold after phosphorylation by
MAPK and GSK3. Thus, dual phosphorylation of rC/EBP/
LAP (Fig. 1B) markedly increased transcription. An unrelated
viral promoter (SV40-driven transcript), included as an internal
control, exhibited 1.5-fold variation between the groups based
on the real-time PCR (data not shown). Other adipocyte-specific
promoters, including those from the C/EBP or SCD1 genes,
were also tested and exhibited substantially increased transcrip-
tion only when rC/EBP/LAP was phosphorylated by both
MAPK and GSK3 (Fig. 3B). These findings indicate that dual
phosphorylation of C/EBP/LAP by MAPK and GSK3 is not
only required for DNA binding activity, but also for transcrip-
tional activation.
Dual Phosphorylation Induces a Conformational Change That Facili-
tates Dimerization and DNA Binding. In studies with an analogous
model system, McKnight’s group used a short C-terminal seg-
ment of C/EBP encompassing the leucine zipper and adjacent
DNA binding domain. Their findings suggested that C/EBP
undergoes conformation-induced dimerization of the leucine
zipper during the binding and release of DNA (15). We consid-
ered the possibility that dual phosphorylation of C/EBP/LAP
might induce a similar conformational change that facilitates
dimerization through the C-terminal leucine zipper and, thereby,
DNA binding (6). To address this hypothesis, rC/EBP/LAP was
phosphorylated and cross-linked with glutaraldehyde. As illus-
trated in Fig. 4A, dimer was generated within 30 sec of exposure
to the cross-linking agent and was markedly facilitated by dual
phosphorylation. At longer times of exposure to glutaraldehyde,
rC/EBP/LAP formed multimers as well as dimers, which was
also increased by phosphorylation. These results suggested that
phosphorylation promoted the interaction between rC/EBP/
LAP monomers, supporting the occurrence of a conformational
change. Given that rC/EBP/LAP exists in equilibrium between
monomeric and dimeric forms, phosphorylation appeared to
shift the equilibrium toward dimer, thereby promoting binding to
the cognate C/EBP regulatory element. Because the use of
glutaraldehyde precluded DNA binding analysis, we sought
another approach to investigate the role of dimerization in DNA
binding (see next paragraph).
Further evidence for a phosphorylation-induced confor-
mational change/dimerization derives from studies in which
rC/EBP/LAP was exposed to mild oxidizing conditions with
oxidized glutathione (GSSG). It is of interest that C/EBP/LAP
possesses five sulfhydryl groups (SH), one of which is C-
Fig. 3. Cell-free transcription of promoter-luciferase genes in the presence
of rC/EBP/LAP (phosphorylated or not by MAPK and/or GSK3) and nuclear
extract. Nuclear extracts (NE) were from 3T3-L1 cells before (day 0) or after
(day 2) induction of differentiation. (A) After incubation with the aP2/422
promoter-luciferase construct, the resulting transcript was isolated and quan-
tified by RT-PCR. (B) Promoter-reporter genes in which the promoters of
various adipocyte genes (the C/EBP, aP2/422, and SCD1 genes) were sub-
jected to cell-free transcription analysis with day-0 nuclear extract and doubly
phosphorylated rC/EBP/LAP as described in A.
Fig. 4. Effect of phosphorylation and dimerization on the DNA binding
activity of rC/EBP/LAP. (A) rC/EBP/LAP was phosphorylated or not with
MAPK and GSK3 and then treated with 0.05% glutaraldehyde for the
indicated times. Proteins were resolved by SDS/10% PAGE and immunoblotted
with anti-C/EBP N-terminal antibody (see Fig. 1C Lower). (B) rC/EBP/LAP
(1 ng) doubly phosphorylated or not with MAPK and GSK3 was mildly
oxidized with 5 mM GSSG for the times indicated, the reaction terminated
with 20 mM iodoacetamide, and the reaction mixture subjected to nonreduc-
ing SDS/PAGE (50 ng) or EMSA (5 ng). (C) Unphosphorylated (N) or doubly
phosphorylated (P) rC/EBP/LAP was incubated with 5 mM GSSG at room
temperature for 30 min and then treated with 1 unit of thrombin. Samples
were resolved by nonreducing SDS/12% PAGE gel and immunoblotted with
anti-C/EBP C-terminal antibody. The arrow on the right identifies the 34-kDa
(17-kDa/17-kDa) dimer of the doubly phosphorylated C-terminal thrombin
cleavage products of the 56-kDa homodimer (upper arrow on left) or residual
uncross-linked monomer (lower arrow on left).
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terminal and abuts the leucine zipper dimerization domain.
Thus, this –SH group pair in the C/EBP/LAP homodimermight
be expected to readily undergo oxidation to form an interchain
disulfide bond that would stabilize the leucine zipper dimer and
create a DNA binding pocket. Thus, we tested the effect of
GSSG-induced oxidation of rC/EBP/LAP on DNA binding
activity before and after dual phosphorylation. When rC/EBP/
LAP was exposed to GSSG, both the un- and dual-phosphory-
lated proteins were converted to dimers (Fig. 4B). Of interest,
however, only doubly phosphorylated rC/EBP/LAP exhibited
DNA binding activity on dimerization. Moreover, phosphoryla-
tion status alone appeared to have little effect on dimerization
caused by GSSG. The close correlation between dimerization
and DNA binding activity of GSSG-treated C/EBP/LAP sug-
gests that dimerization is necessary, but without phosphorylation
is not sufficient to induce a conformation that will bind DNA.
Rather, dual phosphorylation is necessary to induce the ‘‘active’’
conformation. Moreover, comparison of the extent of dimeriza-
tion of unphosphorylated versus phosphorylated rC/EBP/LAP
suggests that dual phosphorylation increases the extent of dimer-
ization (Fig. 4B Upper).
Because C/EBP/LAP possesses five cysteines, numerous
combinations of disulfide bonds between the two monomeric
molecules are possible. To minimize the number of possible
combinations of cysteines involved, we took advantage of the fact
that C/EBP/LAP can be digested with thrombin to generate N-
and C-terminal halves of molecules that have two and three
cysteines, respectively (Fig. 1C). Thus, if two C/EBP/LAP
molecules are connected through any pair of cysteinyl–SH
residues, the resulting 17 kDa from the C-terminal segment
would produce a 34-kDa dimer with nonreducing SDS/PAGE
(see Fig. 4D). Indeed, digestion of phosphorylated and GSSG-
oxidized rC/EBP/LAP with thrombin produced a 34-kDa band
that was not observed in unphosphorylated rC/EBP/LAP (Fig.
4C). This result indicates that only three cysteinyl–SHs (see Fig.
4D Lower) could have given rise to the S–S cross-links in the
full-length native molecule that produced the 34-kDa dimer.
Effect of Mutating Cysteine Residues on DNA Binding Activity. We
focused our efforts on the three cysteine residues (Cys143, Cys201,
and Cys296) located in the C-terminal segment after thrombin
cleavage. The most obvious candidate for S–S bond formation in
a dimer is C296 because this SH group is perfectly juxtaposed next
to the leucine zipper at the C terminus. Each of the three
cysteines in the C-terminal segment of rC/EBP/LAP was
mutated to serine (C143S, C201S, and C296S), expressed and
purified along with Wt as described in Fig. 1. To ascertain which
of these cysteines is important in GSSG-induced disulfide bond
formation, and thereby DNA binding activity, EMSA was con-
ducted before and after phosphorylation. The mutant and Wt
rC/EBP/LAP proteins were equally phosphorylated by MAPK
and GSK3 (Fig. 5A). When subjected to oxidation with GSSG,
the dimerized rC/EBP/LAPs were still observed on the non-
reducing SDS/PAGE presumably because of disulfide bond
formation through the remaining cysteine residues (data not
shown). However, the DNA binding activity was markedly
reduced by the C143S and C296S mutations (Fig. 5A), indicating
that the cysteine residues that bracket the DNA binding domain
are responsible for the oxidation-induced increase of DNA
binding activity. This assertion was verified by the finding that
the double Cys143/296 mutant exhibited even lower DNA binding
activity after dual phosphorylation andGSSG-induced oxidation
(Fig. 5B). Taken together, these findings indicate that phosphor-
ylation of rC/EBP/LAP by MAPK and GSK3 produces a
conformational change that favors dimerization. Although it is
not known whether disulfide bond formation occurs in intact
cells and is required for DNA binding in vivo, oxidation of
rC/EBP/LAP in vitro, together with dual phosphorylation,
promotes even stronger DNA binding.
Model. A model (shown in Fig. 6) is proposed that accounts for
the experimental results presented here and previously (6). We
visualize that C/EBP/LAP is phosphorylated by MAPK imme-
diately (2 h) after induction of differentiation, followed much
later (14 h) by phosphorylation by GSK3 at which point a
conformational change occurs that renders the leucine zipper of
monomeric C/EBP/LAP accessible for dimerization. Dimer-
ization would be expected to bring together the basic regions of
the two monomers to create a ‘‘scissors-like’’ DNA binding
pocket just above the coiled-coil leucine zipper (Fig. 6) as
proposed by McKnight (16). The effect of dimerization on DNA
binding is supported by the fact that mild oxidation by GSSG
creates a disulfide-linked dimer, which, when disrupted by
mutation of Cys143 and Cys296 (Fig. 5B), markedly decreases
DNA binding (Fig. 6). In the cell where disulfide links would not
be expected because of a reducing environment, C/EBP/LAP
would exist in a monomer–dimer equilibrium that would be
shifted to ‘‘active’’ dimer by dual phosphorylation. It should be
noted that under reducing conditions in vitro [i.e., in the presence
of 1 mM dithiothreitol (DTT)], despite the disruption of disul-
fide bond formation, DNA binding occurs but only after dual
phosphorylation (Fig. 2A). The monomer–dimer equilibrium
Fig. 5. Effect of cysteine mutations (Cys143, Cys201, Cys296 singly mutated and
Cys143, Cys296 doubly mutated) in rC/EBP/LAP on DNA-binding activity. The
Cys to Ser mutant recombinant proteins and Wt proteins were prepared and
purified to homogeneity. Identical amounts of the proteins were subjected to
protein staining, phosphorylation with [-32P] or unlabeled ATP, and EMSA.
(A) Effect of single Cys mutations in rC/EBP/LAP. (B) Effect of double Cys
mutations in rC/EBP/LAP.
Fig. 6. Effect of phosphorylation- and dimerization-induced conformational
changes on the DNA binding activity of C/EBP/LAP. Visualized are the effects
of (i) the phosphorylation by MAPK and GSK3 on the conformation and
dimerization of C/EBP/LAP monomer, and (ii) the GSSG-induced Cys-
oxidation/dimerization on the monomer–dimer equilibrium of doubly phos-
phorylated C/EBP/LAP. The size of the DNA symbol is intended to indicate the
tightness of DNA binding.
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would be further shifted to dimer when DNA becomes locked
into the basic DNA binding domain by the scissors grip proposed
by McKnight (16).
Although it is generally assumed but not proven that the
nuclear environment is poised in a reducing state, it would be of
interest to ascertain whether changes in redox state occur in the
nucleus physiologically and whether such changes could affect
disulfide-linked dimerization of C/EBP/LAP.
Materials and Methods
Purification and in Vitro Phosphorylation of rC/EBP/LAP. The cDNA
encoding C/EBP/LAP was cloned into pGEX-6P vector (GE
Healthcare, Piscataway, NJ) and transformed into
BL21(DE3)pLysS (Novagen, Madison, WI). Mutations de-
scribed were introduced by using the QuikChange site-directed
mutagenesis kit (Invitrogen, Carlsbad, CA). The GST-fusion
protein was expressed, purified with glutathione agarose col-
umn, cleaved with PreScrisson Protease (GE Healthcare), and
applied directly to the column. The released recombinant pro-
tein was then further purified by CM-Sepharose ion-exchange
chromatography (GE Healthcare). rC/EBP/LAP was eluted
with 250300 mM NaCl and stored at 80°C until use. Where
indicated, the protein was treated with 1 unit of thrombin (GE
Healthcare). For phosphorylation 500 ng of Wt or mutant
rC/EBP was incubated with activated MAPK and/or GSK3 in
50 mM Hepes (pH 7.6), 10 mMMgCl2, 0.5 mM ATP, and 1 mM
DTT at 30°C for 30 min. Where indicated, 5 Ci of [-32P]ATP
was included.
Cell Culture, Induction of Differentiation, and Nuclear Extract Prepa-
ration. Differentiation of postconfluent 3T3-L1 preadipocytes
(on day 0) was as described (17). Nuclear extracts were prepared
with NUN buffer (1, 18) containing 1 mM DTT for EMSA. For
cell-free transcription assay, nuclear extracts were prepared
from 2-day postconfluent undifferentiated preadipocytes or
from adipocyte 2 days after induction of differentiation (day 2)
by a modification (13) of the protocol of Dignam (19). Nuclear
extracts were dialyzed in 25 mMHepes (pH 7.6), 0.1 mMEDTA,
40 mM KCl, 10% glycerol, and 1 mM DTT and had a final
protein concentration of 34 mg/ml.
EMSA.EMSAwas performed essentially as described (1). Briefly,
labeled probe was incubated with rC/EBP/LAP (110 ng) or
nuclear extract (5 g) in a reaction mixture containing 10 mM
Hepes (pH 7.6), 1 mMEDTA, 7% glycerol, 0.2 (for recombinant
protein) or 1.0 (for crude nuclear extract) g of poly(dIdC), 5 g
of BSA, 100 mM NaCl, and 1 mM DTT. In oxidation-induced
binding experiments, DTT was omitted and 5 mM oxidized
GSSG [prepared in 10 mM Hepes (pH 7.6)] was added. The
C/EBP-binding sequences of adipocyte-specific genes were the
following: C/EBP (4), GGCGT TGCGC CACGA TCTCT CT;
aP2/422 (20), CCAAA GTTGA GAAAT TTCTA TTAA; SCD1
(21), AGGGG GCTGA GGAAA TACTG AACA; PPAR (22),
ACTGC AATTT TAAAA AGCAA TCAA; and GLUT4 (23),
TCAAT TCTTT CAGAA ATTTC GCAG. C/EBP-binding se-
quences are italic.
Cell-Free Transcription. Cell-free transcription was carried out as
described (13, 24) with modification. Briefly, 40 g of nuclear
extract and/or 40 ng of rC/EBP/LAP were incubated with
template DNA (experimental promoter and control; viral pro-
moter: 500 ng and 50 ng, respectively) on ice for 10 min after
which transcription was initiated by adding 0.6 mM each of ATP,
GTP, CTP, and UTP in 40 l containing 10 mMHepes (pH 7.6),
3% glycerol, 25.5 mM KCl, 6 mM MgCl2, 1 mM DTT, and 10
units of RNasin (Promega, Madison, WI). After a 1-h incubation
at 37°C, templates were digested by 20 units of RNase-free
DNase I (Roche Diagnostics, Mannheim, Germany) for 30 min
at 37°C and 370 l containing 20 mM TrisHCl (pH 7.5), 5 mM
EDTA, 1% SDS, 250 mM NaCl, 5 g of tRNA, and 20 g of
proteinase K was added. RNA was recovered by phenol/
chloroform extraction, ethanol precipitation, and centrifugation.
The washed pellet was reverse-transcribed by using random
hexamers and subjected to PCR in the presence of 2 Ci of
[-32P]dCTP for 15 cycles to detect 150 bp of luciferase gene
product. Template DNAs were promoters of C/EBP (205 bp)
(4), 422/aP2 (858 bp) (13), and SCD1 (363 bp) (13) fused to
the luciferase gene. An SV40 viral promoter construct was used
for internal standardization. Transcription products were de-
tected by using real-time PCR.
Glutaraldehyde Cross-Linking or Oxidation of C/EBP, Nonreducing
SDS/PAGE, and Western Blotting. After phosphorylation, rC/EBP
was cross-linked in the presence of 0.05% glutaraldehyde.
Briefly, 50 ng of protein was mixed with glutaraldehyde and
incubated at room temperature for the indicated time. The
reaction was stopped with SDS-containing loading buffer and
subjected to SDS/12% PAGE. Similarly, rC/EBP was treated
with GSSG followed by 20 mM iodoacetamide. Samples were
run in 10% NuPAGE (Invitrogen) without reducing agent. Gels
were transferred onto nitrocellulose membrane and immuno-
blotted with the appropriate antibodies.
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